Table 1C. Hazards ratios of ASPN and BCR; for ASPN mRNA in Mortensen et al, and ASPN H-score in the McGill TMA. Cox analysis of ASPN H-score in patients with Gleason 7 from the McGill TMA.

		Univariate analysis					Multivariate analysis
	N (n)	HR	95% CI	P-value	P-valuea	P-valueb	HR	95% CI	P-value
ASPN	208 (62)	2.52	1.46–5.42	0.002	0.004	0.014	2.30	1.17–4.55	0.016
Age	205 (62)	1.00	0.95–1.04	0.916	0.916	1.000	0.98	0.94–1.03	0.434
Gleason score	208 (62)	2.60	1.58–4.30	1.80E−04	0.001	0.001	2.15	1.22–3.79	0.008
Stage	208 (62)	2.16	1.31–3.56	0.002	0.004	0.014	1.38	0.76–2.52	0.294
PSA	208 (62)	1.03	1.00–1.06	0.060	0.084	0.420	1.00	0.97–1.03	0.956
SM	208 (62)	1.42	0.85–2.39	0.179	0.209	1.000	1.09	0.61–1.93	0.776
SV	208 (62)	3.43	1.55–7.56	0.002	0.004	0.014	2.89	0.89–5.89	0.087

Abbreviations: ASPN=asporin; BCR=biochemical recurrence; CI=confidence interval; FDR=false discovery rate; HR=hazards ratio; PSA=prostate specific antigen; SM=surgical margin; SV=seminal vesicle; TMA=tissue microarray.

Univariate and multivariate Cox analysis of ASPN staining in the McGill TMA cohort subset of patients with a Gleason 7 score. ASPN H-score of >150 showed a hazards ratio of 2.52 (P=0.002) in univariate and 2.30 (P=0.016) in multivariate analysis.

^aFDR-adjusted P-value.

^bBonferroni adjusted P-value. Bold indicates statistically significant values.